Literature DB >> 2375630

Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis.

J D Rothstein1, G Tsai, R W Kuncl, L Clawson, D R Cornblath, D B Drachman, A Pestronk, B L Stauch, J T Coyle.   

Abstract

Recently, the excitatory amino acid neurotransmitter glutamate was implicated in the pathogenesis of a variety of chronic degenerative neurological diseases in humans and animals. This report describes abnormalities in excitatory amino acids in the central nervous system of 18 patients with amyotrophic lateral sclerosis (ALS). The concentration of the excitatory amino acids glutamate and aspartate in the cerebrospinal fluid were increased significantly (p less than 0.01) by 100 to 200% in patients with ALS. Similarly, the concentrations of the excitatory neuropeptide N-acetyl-aspartyl glutamate and its metabolite, N-acetyl-aspartate, were elevated twofold to threefold in the cerebrospinal fluid from the patients. There was no relationship between amino acid concentrations and duration of disease, clinical impairment, or patient age. In the ventral horns of the cervical region of the spinal cord, the level of N-acetyl-aspartyl glutamate and N-acetyl-aspartate was decreased by 60% (p less than 0.05) and 40% (p less than 0.05), respectively, in 8 patients with ALS. Choline acetyltransferase activity was also diminished by 35% in the ventral horn consistent with motor neuron loss. We conclude that excitatory amino acid metabolism is altered in patients with ALS. Based on neurodegenerative disease models, these changes may play a role in motor neuron loss in ALS.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2375630     DOI: 10.1002/ana.410280106

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  133 in total

Review 1.  Molecular mechanisms regulating motor neuron development and degeneration.

Authors:  T J Kilpatrick; M Soilu-Hänninen
Journal:  Mol Neurobiol       Date:  1999-06       Impact factor: 5.590

Review 2.  Progress in the pathogenesis of amyotrophic lateral sclerosis.

Authors:  C E Shaw; A al-Chalabi; N Leigh
Journal:  Curr Neurol Neurosci Rep       Date:  2001-01       Impact factor: 5.081

3.  Fragmentation of the Golgi apparatus of motor neurons in amyotrophic lateral sclerosis.

Authors:  N K Gonatas; A Stieber; Z Mourelatos; Y Chen; J O Gonatas; S H Appel; A P Hays; W F Hickey; J J Hauw
Journal:  Am J Pathol       Date:  1992-03       Impact factor: 4.307

Review 4.  Glutamate transporter 1: target for the treatment of alcohol dependence.

Authors:  P S S Rao; Y Sari
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

5.  The preclinical discovery of amyotrophic lateral sclerosis drugs.

Authors:  Marcie A Glicksman
Journal:  Expert Opin Drug Discov       Date:  2011-10-25       Impact factor: 6.098

6.  Riluzole does not have an acute effect on motor thresholds and the intracortical excitability in amyotrophic lateral sclerosis.

Authors:  M Sommer; F Tergau; S Wischer; C D Reimers; W Beuche; W Paulus
Journal:  J Neurol       Date:  1999-11       Impact factor: 4.849

7.  Compromised glutamate transport in human glioma cells: reduction-mislocalization of sodium-dependent glutamate transporters and enhanced activity of cystine-glutamate exchange.

Authors:  Z C Ye; J D Rothstein; H Sontheimer
Journal:  J Neurosci       Date:  1999-12-15       Impact factor: 6.167

8.  Harmine, a natural beta-carboline alkaloid, upregulates astroglial glutamate transporter expression.

Authors:  Yun Li; Rita Sattler; Eun Ju Yang; Alice Nunes; Yoko Ayukawa; Sadia Akhtar; Grace Ji; Ping-Wu Zhang; Jeffrey D Rothstein
Journal:  Neuropharmacology       Date:  2010-10-27       Impact factor: 5.250

9.  C9orf72 Dipeptide Repeats Cause Selective Neurodegeneration and Cell-Autonomous Excitotoxicity in Drosophila Glutamatergic Neurons.

Authors:  Wangchao Xu; Jin Xu
Journal:  J Neurosci       Date:  2018-07-23       Impact factor: 6.167

10.  D-serine is a key determinant of glutamate toxicity in amyotrophic lateral sclerosis.

Authors:  Jumpei Sasabe; Tomohiro Chiba; Marina Yamada; Koichi Okamoto; Ikuo Nishimoto; Masaaki Matsuoka; Sadakazu Aiso
Journal:  EMBO J       Date:  2007-08-30       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.